New Survey Reveals High Expectations for Popular Aesthetic Injections

Americans Want a More Natural Look and Fast Results

SCOTTSDALE, Ariz., July 7 /PRNewswire/ -- Americans aren't willing to give up
aesthetic injections and interest is growing, whether as a means to stay
competitive in today's job market or simply to maintain a youthful image, the
demand and want is strong. At the time of a recent Kelton Research* survey
more than 40 percent of respondents were interested in receiving aesthetic
botulinum toxin injections within the next six months.(1)

Despite clear interest, many expressed reluctance to having a botulinum toxin
injection. In fact, one-third of those who had not yet received the treatment
were worried that it would prevent them from being able to make natural facial
expressions.(1)

Sixty-three percent of survey respondents who would ever consider receiving
botulinum toxin injections cited that a guarantee of natural-looking results
would influence their decision, demonstrating a desire for retaining a
natural-looking face, and more natural-looking expressions following
injection.(1) Other top factors included more affordable costs, longer-lasting
and faster-acting results.(2)

The poll found that of the respondents who had never undergone botulinum toxin
injections, 36% said that their concern about no longer having a natural look
had prevented them from receiving the treatmentin the past.(1) Almost 60
percent of those surveyed who had not ever received an injection stated that
they'd be likely to if the cost of treatment was more affordable.(1) And, of
the respondents who had botulinum toxin injections, three in ten reported not
seeing noticeable results for at least a week(1) and thirty percent of polled
respondents said that having immediate results, such as within 24-48 hours,
would positively influence their decision to undergo treatment.(2)

According to Florida dermatologist Dr. Susan Weinkle, patients want value and
rapid results at a fair price. "My patients are looking for a treatment that
will not make them look obvious or overdone and they want these natural
looking results fast."

They are in luck: after extensive testing and clinical results, a new
Botulinum Toxin A is now on the market. Dysport(TM) has been approved by the
FDA for use in the United States for the temporary improvement in the
appearance of moderate to severe glabellar lines - the vertical lines between
the eyebrows - in adult men and women 65 or younger.
The benefits of Dysport(TM) include:
-- Duration - results lasting up to four months
-- Demonstrated efficacy with four repeat treatments (proving results
following each treatment)
-- Demonstrated safety with 12 repeat treatments
-- No evidence of neutralizing antibodies
-- Clinical trials included both subjects who have and have not
previously
been treated with a Botulinum Toxin. There was no difference in
results
among the two groups
-- Large patient population - 4,800 treatments in 2,900 patients (with an
ethnically diverse population)

*About the 2009 Botulinum Toxin survey:
Sample: 600 U.S. adults ages 25-60 with a household income of $50,000 or more,
including 570 females and 300 botulinum toxin users and 300 aware of at least
one nonsurgical aesthetic procedure or treatment.(2)

References:

1. Kelton Research. Botulinum Toxin Survey NewsWorthy Analysis.
February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

2. Kelton Research. Botulinum Toxin Survey Topline Report. February--March
2009. Data on file, Medicis Pharmaceutical Corporation.

Important Safety Information
Dysport(TM) is an acetylcholine release inhibitor and a neuromuscular blocking
agent indicated for the temporary improvement in appearance of moderate to
severe glabellar lines associated with procerus and corrugator muscle activity
in adult patients.

Botulinum toxin effects may spread beyond the site of local injection to
produce systemic symptoms of botulism such as swallowing and breathing
difficulties that can occur within hours to weeks of injection. The risk of
symptoms is probably greatest in children treated for spasticity, but symptoms
can also occur in adults, particularly in those patents who have underlying
conditions that would predispose them to these symptoms. In clinical trials,
the most frequently reported adverse effects (>2%) are headache,
nasopharyngitis and upper respiratory tract infection.

Dysport(TM) is not recommended for children or pregnant women. Re-treatment
with Dysport(TM) should be administered no more than every three months.

SOURCE Medicis Aesthetics Inc.

Ilisa Wirgin or Elyse Koenig, LaForce + Stevens, +1-212-242-9353